Comparative analysis of gene expression platforms for cell-of-origin classification of diffuse large B-cell lymphoma shows high concordance

被引:7
|
作者
Ahmed, Sophia [1 ]
Glover, Paul [2 ]
Taylor, Jan [2 ]
Sha, Chulin [1 ]
Care, Matthew A. [3 ]
Tooze, Reuben [2 ,3 ]
Davies, Andrew [4 ]
Westhead, David R. [1 ]
Johnson, Peter W. M. [4 ]
Burton, Catherine [2 ]
Barrans, Sharon L. [2 ]
机构
[1] Univ Leeds, Fac Biol Sci, Leeds, W Yorkshire, England
[2] St James Univ Hosp, Haematol Malignancy Diagnost Serv, Leeds LS9 7TF, W Yorkshire, England
[3] Univ Leeds, Fac Med, Leeds, W Yorkshire, England
[4] Univ Southampton, Canc Res UK Ctr, Southampton Clinical Trials Unit, Southampton, Hants, England
关键词
diffuse large B cell lymphoma; genetic subtyping; gene expression; cell of origin; lymphomas;
D O I
10.1111/bjh.17246
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cell-of-origin subclassification of diffuse large B cell lymphoma (DLBCL) into activated B cell-like (ABC), germinal centre B cell-like (GCB) and unclassified (UNC) or type III by gene expression profiling is recommended in the latest update of the World Health Organization's classification of lymphoid neoplasms. There is, however, no accepted gold standard method or dataset for this classification. Here, we compare classification results using gene expression data for 68 formalin-fixed paraffin-embedded DLBCL samples measured on four different gene expression platforms (Illumina wG-DASL(TM) arrays, Affymetrix PrimeView arrays, Illumina TrueSeq RNA sequencing and the HTG EdgeSeq DLBCL Cell of Origin Assay EU using an established platform agnostic classification algorithm (DAC) and the classifier native to the HTG platform, which is CE marked for in vitro diagnostic use (CE-IVD). Classification methods and platforms show a high level of concordance, with agreement in at least 80% of cases and rising to much higher levels for classifications of high confidence. Our results demonstrate that cell-of-origin classification by gene expression profiling on different platforms is robust, and that the use of the confidence value alongside the classification result is important in clinical applications.
引用
收藏
页码:599 / 604
页数:6
相关论文
共 50 条
  • [1] Cell-of-origin classification by gene expression and MYC-rearrangements in diffuse large B-cell lymphoma of children and adolescents
    Szczepanowski, Monika
    Lange, Jonas
    Kohler, Christian W.
    Masque-Soler, Neus
    Zimmermann, Martin
    Aukema, Sietse M.
    Altenbuchinger, Michael
    Rehberg, Thorsten
    Mahn, Friederike
    Siebert, Reiner
    Spang, Rainer
    Burkhardt, Birgit
    Klapper, Wolfram
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 179 (01) : 116 - 119
  • [2] Comparative molecular cell-of-origin classification of diffuse large B-cell lymphoma based on liquid and tissue biopsies
    Ewan Hunter
    Ronald McCord
    Aroul S. Ramadass
    Jayne Green
    Jurjen W. Westra
    Kirsten Mundt
    Alexandre Akoulitchev
    Translational Medicine Communications, 5 (1)
  • [3] Cell-of-Origin Subtype Prediction of Diffuse Large B-Cell Lymphoma Using Gene Expression and Proteomic Data
    Liu, Huiqing
    Lu, Jin
    Dong, Zhiwan
    Liu, Hao
    Salinas, Edward
    Owens, Sherry
    Pratta, Michael A.
    Smith, Michael F.
    Tada, Hiroomi
    Newton, Robert C.
    Burn, Timothy
    BLOOD, 2018, 132
  • [4] Cell-of-origin is an important biomarker in diffuse large B-cell lymphoma (DLBCL)
    Farinha, P
    Bebb, G
    Siebert, R
    Horsman, D
    Connors, JM
    Gascoyne, RD
    MODERN PATHOLOGY, 2005, 18 : 229A - 229A
  • [5] Cell-of-origin is an important biomarker in diffuse large B-cell lymphoma (DLBCL)
    Farinha, P
    Bebb, G
    Siebert, R
    Horsman, D
    Connors, JM
    Gascoyne, RD
    LABORATORY INVESTIGATION, 2005, 85 : 229A - 229A
  • [6] Noninvasive Cell-of-Origin Classification of Diffuse Large B-Cell Lymphoma Using Inferred Gene Expression from Cell-Free DNA Sequencing
    Esfahani, Mohammad Shahrokh
    Alig, Stefan
    Mehrmohamadi, Mahya
    Hamilton, Emily G.
    King, Daniel A.
    Schultz, Andre
    Steen, Chloe B.
    Macaulay, Charles
    Sworder, Brian
    Kurtz, David M.
    Diehn, Maximilian
    Alizadeh, Ash A.
    BLOOD, 2021, 138
  • [7] CD79 Expression Is Associated with Cell-of-Origin and Outcome in Diffuse Large B-Cell Lymphoma
    Naoi, Yusuke
    Chijimatsu, Ryota
    Urata, Tomohiro
    Sunami, Kazutaka
    Imai, Toshi
    Nawa, Yuichiro
    Hiramatsu, Yasushi
    Yamamoto, Kazuhiko
    Fujii, Soichiro
    Yoshida, Isao
    Yano, Tomofumi
    Ikeuchi, Kazuhiro
    Kobayashi, Hiroki
    Tani, Katsuma
    Murakami, Hiroyuki
    Ujiie, Hideki
    Sato, Yasuharu
    Takata, Katsuyoshi
    Boyle, Merrill
    Jiang, Aixiang
    Maeda, Yoshinobu
    Scott, David W.
    Ennishi, Daisuke
    BLOOD, 2023, 142
  • [8] Integrated Analysis of IGHV Gene Status, Cell-of-Origin Signature and Genomic Features in Diffuse Large B-Cell Lymphoma
    Etancelin, Pascaline
    Dubois, Sydney
    Viailly, Pierre-Julien
    Bohers, Elodie
    Bertrand, Philippe
    Ruminy, Philippe
    Maingonnat, Catherine
    Picquenot, Jean-Michel
    Mareschal, Sylvain
    Jais, Jean-Philippe
    Tesson, Bruno
    Peyrouze, Pauline
    Figeac, Martin
    Fest, Thierry
    Haioun, Corinne
    Lamy, Thierry
    Copie-Bergman, Christiane
    Fabiani, Bettina
    Delarue, Richard
    Peyrade, Frederic
    Marc, Andre
    Ketterer, Nicolas
    Leroy, Karen
    Salles, Gilles A.
    Molina, Thierry Jo
    Tilly, Herve
    Stevenson, Freda K.
    Jardin, Fabrice
    BLOOD, 2016, 128 (22)
  • [9] Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis
    Russler-Germain, David A.
    Cliff, Edward R. Scheffer
    Bartlett, Nancy L.
    BLOOD, 2023, 142 (25) : 2216 - 2219
  • [10] Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies
    Coutinho, Rita
    Clear, Andrew James
    Owen, Andrew
    Wilson, Andrew
    Matthews, Janet
    Lee, Abigail
    Alvarez, Rute
    da Silva, Maria Gomes
    Cabecadas, Jose
    Calaminici, Maria
    Gribben, John G.
    CLINICAL CANCER RESEARCH, 2013, 19 (24) : 6686 - 6695